Bicara Therapeutics Inc. Common Stock

BCAX · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$36,330-$27,388-$36,846-$20,957
Dep. & Amort.$24$19$19$15
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$3,492$3,451$3,181
Change in WC$3,163-$1,928$5,132-$11,995
Other Non-Cash$3,895$211$138-$276
Operating Cash Flow-$29,248-$25,594-$28,106-$30,032
Investing Activities
PP&E Inv.-$42$0$0-$40
Net Acquisitions$0$0$0$0
Inv. Purchases-$236,079$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$236,121$0$0-$40
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$436$135$460-$1,052
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$77
Financing Cash Flow$436$135$460-$975
Forex Effect$0$0$0$0
Net Chg. in Cash-$264,933-$25,459-$27,646-$31,047
Supplemental Information
Beg. Cash$436,606$462,065$489,711$520,758
End Cash$171,673$436,606$462,065$489,711
Free Cash Flow-$29,290-$25,594-$28,106-$30,072
Bicara Therapeutics Inc. Common Stock (BCAX) Financial Statements & Key Stats | AlphaPilot